Politico | How a Lack of FDA Inspections Will Likely Lead to Drug Rejections

Cathy Burgess is quoted on COVID-19 safety considerations for Food and Drug Administration inspections.

Cathy Burgess is quoted on how the Food and Drug Administration might conduct remote inspections of drug manufacturing facilities amid COVID-19.

Cathy Burgess is quoted on how the U.S. FDA’s Center for Drug Evaluation and Research could potentially handle the expiration of COVID-19-related emergency use authorizations it has issued for drug products.

Cathy Burgess is quoted on recent guidance by the U.S. Food and Drug Administration that could include virtual inspections of manufacturing sites amid COVID-19 and how the industry should continue urging the FDA to adopt these new approaches.

This week, CMS released guidance on the Medicare Prescription Payment Plan, which allows Medicare beneficiaries to pay prescription costs in monthly installments, and the House held a legislative hearing on 19 bipartisan health care legislations.